Pioneering biosimilars

At Sandoz, we are playing a pioneer role in developing the exciting new field of biosimilars, which promise major savings to patients and healthcare systems worldwide.

With decades of experience in biotechnology, a global development and production network and an unrivalled reputation for quality, Sandoz is ideally placed to capture the biosimilars opportunity. Indeed, we are already at the forefront of bringing affordable high-quality biosimilars to patients once patents expire.

Following the precedent-setting launch of human growth hormone Omnitrope® in both the EU and the US, we have now also marketed the first truly complex biosimilar (anemia medicine Binocrit® / Epoetin Alfa® HEXAL) in the EU, followed by groundbreaking oncology medicine Zarzio® / Filgrastim®^_.

Building in quality by design

To develop biosimilars, requires expertise. Sandoz, which has been involved in biopharmaceutical production for several decades, knows better than most.

At the heart of our approach is a concept we refer to as "quality by design" - effectively, ensuring quality by designing manufacturing processes that guarantee comparability with the original product.

It is an approach that has been tried, tested and proved to work in practice, giving us a major edge over would-be competitors.